The for-profit oncology group which holds roughly half the UK's proton beam capacity and has invested over £240m in capex is to go into liquidation, thanks to the pandemic and NHS indifference. In the UK just 1% of acute cancer patients get proton compared to 10% in Europe and 20% in the USA. What is likely to happen next?